180307-02-2

Usage

Imidazole ring

A five-membered aromatic ring with two nitrogen atoms at positions 1 and 3, contributing to its stability and potential for coordination with metal ions.

Trifluoromethyl group

A highly electronegative group (CF3) that can influence the compound's reactivity, stability, and lipophilicity.

Phenoxy group

An oxygen atom bonded to a phenyl ring, which may contribute to the compound's solubility, stability, and potential for hydrogen bonding.

Ethyl group

A two-carbon alkyl chain (C2H5) that can provide flexibility and steric hindrance, affecting the compound's reactivity and interactions with other molecules.

Potential applications

Due to its complex structure and various functional groups, 1H-Imidazole, 4-[2-[4-(trifluoromethyl)phenoxy]ethyl]-1-(triphenylmethyl)- may have uses in pharmaceuticals, agrochemicals, and materials science, but further research is needed to determine its specific applications and effects.

Upstream product

• 402-45-9 4-hydroxybenzotrifluoride 
• 127607-62-9 1-triphenylmethyl-4-(2-hydroxyethyl)-1H-imidazole 
• 76-83-5 trityl chloride 
• 1972-28-7 diethylazodicarboxylate 

Relevant academic research and scientific papers

A novel series of (phenoxyalkyl)imidazoles as potent H3-receptor histamine antagonists

[[(4-Nitrophenyl)X]alkyl]imidazole isosteres (where X = NH, S, CH2S, O) of previously described [[(5-nitropyrid-2-yl)X]ethyl]imidazoles (where X = NH, S) have been synthesized and evaluated for H3-receptor histamine antagonism in vitro (K(i) for [3H]histamine release from rat cerebral cortex synaptosomes) and in vivo (ED50 per os in mice on brain tele- methylhistamine levels). Encouraging results led to the synthesis and testing of a novel series of substituted (phenoxyethyl)- and (phenoxypropyl)imidazoles. From the latter, 4-[3-(4-cyanophenoxy)propyl]-1H- imidazole (10a, UCL 1390; K(i) = 12 nM, ED50 = 0.54 mg/kg) and 4-[3-[4- (trifluoromethyl)-phenoxy]propyl]-1H-imidazole (10c, UCL 1409; K(i) = 14 nM, ED50 = 0.60 mg/kg) have been selected as potential candidates for drug development. For 16 [(aryloxy)ethyl]imidazoles the relationship between in vitro and in vivo potency is described by the equation log ED50 = 0.47 log K(i) + 0.20 (r = 0.78).

Imidazole compounds and their therapeutic applications

A compound selected from the group consisting of a compound of the formulawherein the substituents are defined as in the specification having antagonist properties to histamine H3-receptors.